Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Beyond Air, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GARDEN CITY, N.Y., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR) (BEYOND AIR OR THE COMPANY), A COMMERCIAL STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING THE POWER OF NITRIC OXIDE (NO) TO IMPROVE THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT DOUGLAS LARSON, CHIEF FINANCIAL OFFICER OF BEYOND AIR, WILL PARTICIPATE IN THE ROTH 4TH ANNUAL HEALTHCARE OPPORTUNITIES CONFERENCE, WHICH IS BEING HELD ON THURSDAY, OCTOBER 9, 2025, IN NEW YORK, NY.

BEYOND AIR TO PARTICIPATE IN THE ROTH 4TH ANNUAL HEALTHCARE OPPORTUNITIES CONFERENCE

GARDEN CITY, N.Y., SEPT. 08, 2025 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR) (BEYOND AIR OR THE COMPANY), A COMMERCIAL STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING THE POWER OF NITRIC OXIDE (NO) TO IMPROVE THE LIVES OF PATIENTS, TODAY ANNOUNCED THE ENTRY INTO A DEFINITIVE AGREEMENT FOR THE IMMEDIATE EXERCISE OF CERTAIN OUTSTANDING COMMON WARRANTS (THE EXISTING WARRANTS) TO PURCHASE UP TO AN AGGREGATE OF 1,439,126 SHARES OF THE COMPANY'S COMMON STOCK AT A REDUCED EXERCISE PRICE OF $2.21 (THE CLOSING PRICE OF THE COMPANY'S SHARES OF COMMON STOCK ON SEPTEMBER 5, 2025). THE GROSS PROCEEDS TO THE COMPANY FROM THE EXERCISE OF THE WARRANTS ARE EXPECTED TO BE APPROXIMATELY $3.25 MILLION, PRIOR TO DEDUCTING PLACEMENT AGENT FEES AND ESTIMATED OFFERING EXPENSES.

BEYOND AIR ANNOUNCES EXERCISE OF WARRANTS FOR $3.25 MILLION OF GROSS PROCEEDS

GARDEN CITY, N.Y., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR) (BEYOND AIR OR THE COMPANY), A COMMERCIAL STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING THE POWER OF NITRIC OXIDE (NO) TO IMPROVE THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT STEVE LISI, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF BEYOND AIR, WILL PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE BEING HELD SEPTEMBER 8-10, 2025 IN NEW YORK, NY.

BEYOND AIR TO PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

THESE RECENT LUNGFIT PH INTERNATIONAL AGREEMENTS BRING THE EX-U.S. TOTAL TO 34 COUNTRIES AND A COMBINED POPULATION OF 2.7 BILLION PEOPLE THESE RECENT LUNGFIT PH INTERNATIONAL AGREEMENTS BRING THE EX-U.S. TOTAL TO 34 COUNTRIES AND A COMBINED POPULATION OF 2.7 BILLION PEOPLE

BEYOND AIR SIGNS NEW INTERNATIONAL LUNGFIT PH DISTRIBUTION AGREEMENTS, MOST NOTABLY IN JAPAN

GARDEN CITY, N.Y., JULY 25, 2025 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR) (BEYOND AIR OR THE COMPANY), A COMMERCIAL STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING THE POWER OF NITRIC OXIDE (NO) TO IMPROVE THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR ITS FIRST FISCAL QUARTER ENDED JUNE 30, 2025 ON TUESDAY, AUGUST 12, 2025. THE COMPANY'S MANAGEMENT TEAM IS SCHEDULED TO HOST A CONFERENCE CALL AND WEBCAST AT 4:30 PM EASTERN TIME THE SAME DAY.

BEYOND AIR SCHEDULES FIRST FISCAL QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST

GARDEN CITY, N.Y., JULY 22, 2025 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR) (BEYOND AIR OR THE COMPANY), A COMMERCIAL STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING THE POWER OF NITRIC OXIDE (NO) TO IMPROVE THE LIVES OF PATIENTS, HAS BEEN AWARDED A NATIONAL GROUP PURCHASING AGREEMENT FOR THERAPEUTIC GASES WITH PREMIER, INC. EFFECTIVE JULY 15TH, THE NEW AGREEMENT ALLOWS PREMIER MEMBERS, AT THEIR DISCRETION, TO TAKE ADVANTAGE OF SPECIAL PRICING AND TERMS PRE-NEGOTIATED BY PREMIER FOR THE LUNGFIT PH SYSTEM AND DISPOSABLE NO2 SMART FILTERS.

BEYOND AIR AWARDED THERAPEUTIC GASES AGREEMENT WITH PREMIER, INC.

MEDICAL OPINION CONCLUDES THAT BEYOND OIL HAS POTENTIAL TO REDUCE GASTROINTESTINAL CANCER RISK AMONG CONSUMERS OF FRIED FOODS AND FOOD SERVICE WORKERS MEDICAL OPINION CONCLUDES THAT BEYOND OIL HAS POTENTIAL TO REDUCE GASTROINTESTINAL CANCER RISK AMONG CONSUMERS OF FRIED FOODS AND FOOD SERVICE WORKERS

BEYOND OIL ANNOUNCES PUBLICATION OF EXPERT MEDICAL OPINION BY PROF. ILAN RON, SPECIALIST IN CLINICAL AND RADIATION ONCOLOGY, REGARDING THE RISKS ASSOCIATED WITH EXPOSURE TO FRYING OILS AS CONTRIBUTORS TO NEOPLASTIC MUTATIONS IN BODY TISSUE

REVENUES INCREASED 220% TO $3.7 MILLION, COMPARED WITH $1.2 MILLION FOR THE FISCAL YEAR ENDED MARCH 31, 2024 EXPECT TO REPORT REVENUE OF AT LEAST $1.7 MILLION FOR QUARTER ENDING JUNE 30, 2025, AND INTRODUCING REVENUE GUIDANCE OF $12-$16 MILLION FOR THE FULL FISCAL YEAR 2026 SUBMITTED PMA SUPPLEMENT FOR SECOND-GENERATION LUNGFIT PH TO FDA INTERNATIONAL DISTRIBUTION PARTNERSHIPS NOW PROVIDE ACCESS TO MARKETS REPRESENTING OVER 2 BILLION LIVES, WITH LUNGFIT PH ACTIVELY SHIPPING TO EUROPE, AUSTRALIA, AND THE MIDDLE EAST APPOINTED ROBERT GOODMAN, A COMMERCIAL FOCUSED SEASONED HEALTHCARE EXECUTIVE, TO THE COMPANY'S BOARD OF DIRECTORS CONFERENCE CALL AT 4:30 P.M. ET TODAY, JUNE 17 TH  GARDEN CITY, N.Y.

BEYOND AIR REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

LUNGFIT PH II'S SMALLER, LIGHTWEIGHT, TRANSPORT-READY DESIGN IS EXPECTED TO OPEN THE ENTIRETY OF THE NO MARKET FINAL DESIGN BASED UPON SUBSTANTIAL FEEDBACK FROM RESPIRATORY THERAPISTS ACROSS THE COUNTRY GARDEN CITY, N.Y., JUNE 16, 2025 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR) (BEYOND AIR OR THE COMPANY), A COMMERCIAL STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING THE POWER OF NITRIC OXIDE (NO) TO IMPROVE THE LIVES OF PATIENTS, TODAY ANNOUNCED THE SUBMISSION OF A PREMARKET APPROVAL (PMA) SUPPLEMENT APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR LUNGFIT PH II, THE NEXT-GENERATION THERAPEUTIC NITRIC OXIDE GENERATOR.

BEYOND AIR SUBMITS FDA PMA SUPPLEMENT FOR NEXT GENERATION LUNGFIT PH

VANCOUVER, BC AND KIBBUTZ YIFAT, ISRAEL, JUNE 03, 2025 (GLOBE NEWSWIRE) -- AS A RESULT OF A REVIEW BY THE BRITISH COLUMBIA SECURITIES COMMISSION (THE BCSC), BEYOND OIL LTD. (CSE: BOIL; OTCQB: BEOLF; FRANKFURT: UH9) (BEYOND OIL OR THE COMPANY) TODAY ISSUED THE FOLLOWING PRESS RELEASE PROVIDING CLARIFICATIONS RELATED TO CERTAIN GERMAN-LANGUAGE PROMOTIONAL MEDIA ACTIVITIES.

Beyond Air, Inc.

XAIR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Beyond Air, Inc.

XAIR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

XAIR